Literature DB >> 26281768

Theoretical considerations for thresholds in chemical carcinogenesis.

Adam D Thomas1, Jörg Fahrer1, George E Johnson2, Bernd Kaina3.   

Abstract

There is increasing evidence for non-linear relationships for gene mutations, chromosomal aberrations and even tumor incidences in response to low doses of genotoxic carcinogens. To attain the biological relevance of such non-linear responses, there is a need to identify the underlying defense mechanisms that allow tolerance to low doses of genotoxicants. This communication discusses presumptive cancer prevention mechanisms that may contribute to thresholds, i.e. points of departure, for each endpoint, from initial DNA lesion to tumor formation. We discuss a sequential order of genome protection during carcinogenesis where genotoxicant scavenging, cellular efflux, DNA repair, elimination of damaged cells by apoptosis, autophagy, silencing by DNA damage-triggered replicative senescence, and finally, elimination of transformed (premalignant) cells by the immune system are thought to be responsible for a threshold in tumor formation. We highlight DNA repair, for which experimental evidence has been recently provided to dictate a role in PoDs. In conclusion, from a theoretical perspective it is reasonable to posit that tolerance to low dose levels exists for each requisite step of tumor formation and these tolerance mechanisms are critical in determining thresholds in chemical carcinogenesis.
Copyright © 2015 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Apoptosis; Carcinogens; Cell death; DNA repair; Detoxification; MGMT; PoD; Threshold

Mesh:

Substances:

Year:  2015        PMID: 26281768     DOI: 10.1016/j.mrrev.2015.05.001

Source DB:  PubMed          Journal:  Mutat Res Rev Mutat Res        ISSN: 1383-5742            Impact factor:   5.657


  8 in total

Review 1.  Mode of action-based risk assessment of genotoxic carcinogens.

Authors:  Andrea Hartwig; Michael Arand; Bernd Epe; Sabine Guth; Gunnar Jahnke; Alfonso Lampen; Hans-Jörg Martus; Bernhard Monien; Ivonne M C M Rietjens; Simone Schmitz-Spanke; Gerlinde Schriever-Schwemmer; Pablo Steinberg; Gerhard Eisenbrand
Journal:  Arch Toxicol       Date:  2020-06-15       Impact factor: 5.153

Review 2.  Contributions of DNA repair and damage response pathways to the non-linear genotoxic responses of alkylating agents.

Authors:  Joanna Klapacz; Lynn H Pottenger; Bevin P Engelward; Christopher D Heinen; George E Johnson; Rebecca A Clewell; Paul L Carmichael; Yeyejide Adeleye; Melvin E Andersen
Journal:  Mutat Res Rev Mutat Res       Date:  2015-12-02       Impact factor: 5.657

3.  High-Throughput Screening Platform for Nanoparticle-Mediated Alterations of DNA Repair Capacity.

Authors:  Sneh M Toprani; Dimitrios Bitounis; Qiansheng Huang; Nathalia Oliveira; Kee Woei Ng; Chor Yong Tay; Zachary D Nagel; Philip Demokritou
Journal:  ACS Nano       Date:  2021-03-12       Impact factor: 15.881

Review 4.  Aptamers for DNA Damage and Repair.

Authors:  Maureen McKeague
Journal:  Int J Mol Sci       Date:  2017-10-22       Impact factor: 5.923

5.  Benchmark dose analyses of multiple genetic toxicity endpoints permit robust, cross-tissue comparisons of MutaMouse responses to orally delivered benzo[a]pyrene.

Authors:  Alexandra S Long; John W Wills; Dorothy Krolak; Matthew Guo; Stephen D Dertinger; Volker M Arlt; Paul A White
Journal:  Arch Toxicol       Date:  2017-11-24       Impact factor: 5.153

Review 6.  What is the meaning of 'A compound is carcinogenic'?

Authors:  Dieter Schrenk
Journal:  Toxicol Rep       Date:  2018-04-07

7.  Biological Basis for Threshold Responses to Methylating Agents.

Authors:  Adam D Thomas
Journal:  Chem Res Toxicol       Date:  2020-05-27       Impact factor: 3.739

8.  Cucurbitacin B inhibits TGF-β1-induced epithelial-mesenchymal transition (EMT) in NSCLC through regulating ROS and PI3K/Akt/mTOR pathways.

Authors:  Renyikun Yuan; Qiumei Fan; Xiaowei Liang; Shan Han; Jia He; Qin-Qin Wang; Hongwei Gao; Yulin Feng; Shilin Yang
Journal:  Chin Med       Date:  2022-02-19       Impact factor: 5.455

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.